Stéphane Bancel, Moderna CEO (JPM20/Jeff Rumans)

Mod­er­na says it's reached the re­quired num­ber of Covid-19 cas­es for its first in­ter­im analy­sis. When is the read­out com­ing?

Pfiz­er and BioN­Tech came out with the first Phase III in­ter­im analy­sis of their Covid-19 vac­cine ear­li­er this week, and it ap­pears Mod­er­na is right on their heels.

The Cam­bridge, MA-based biotech an­nounced Wednes­day af­ter­noon that it has reached the thresh­old re­quired to con­duct its own ini­tial Phase III in­ter­im analy­sis. And as a re­sult of a “sig­nif­i­cant in­crease” in tri­al par­tic­i­pants con­tract­ing con­firmed cas­es of Covid-19, Mod­er­na al­so ex­pects the analy­sis will in­clude “sub­stan­tial­ly more” than the 53 cas­es orig­i­nal­ly set out for the analy­sis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.